Teknova Announces Closing of $15.4 Million Private Placement
Alpha Teknova has closed a $15.4 million private placement involving the issuance of 12,385,883 shares at $1.24 each, based on the Nasdaq closing price on July 11, 2024.
The gross proceeds from this private placement are approximately $15.4 million, before expenses. The funds will be used for general corporate purposes.
The securities from this transaction are not registered under the Securities Act and can only be resold under specific conditions. This announcement does not constitute an offer to sell or buy these securities in jurisdictions where such actions are unlawful.
- Raised $15.4 million through private placement.
- Issued 12,385,883 shares at $1.24 each.
- Potential shareholder dilution due to issuance of 12,385,883 new shares.
- Expenses will reduce the net proceeds from $15.4 million.
Insights
The private placement raised
For retail investors, it indicates that the company has successfully secured funds, which can be seen as a positive sign of confidence from institutional investors. The funds will be used for general corporate purposes, a broad term that could encompass anything from research and development to expanding operational capacity.
However, it's essential to consider the potential dilution of existing shares since 12,385,883 new shares have been issued. While the influx of capital can drive growth, the increase in the number of shares could potentially dilute the value of existing shares unless the company performs exceptionally well with the new capital.
In the short-term, the stock might experience some volatility as the market absorbs the news. In the long-term, the success of this move will largely depend on how effectively Teknova utilizes the additional funds to enhance its business operations and achieve growth.
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of
The gross proceeds to Teknova from the private placement are approximately
The offer and sale of the securities in the private placement occurred in transactions not involving a public offering and the securities have not been registered pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(b) of Regulation D promulgated thereunder, nor have they been registered under the Securities Act or applicable state securities laws. Accordingly, the securities sold in the private placement may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, Teknova’s expectations regarding the anticipated use of proceeds from the offering. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with market conditions; demand for Teknova’s products (including the potential delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the SEC, including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
FAQ
What is the amount raised by Teknova in the recent private placement?
How many shares did Teknova issue in the private placement?
What was the purchase price per share in Teknova's private placement?
What will Teknova use the funds from the private placement for?
Are the securities from Teknova's private placement registered under the Securities Act?
